Weaker Buy Today ACRS ranks #2008 as BUY CANDIDATE. Stronger Buy
Today ACRS ranks #2008 as BUY CANDIDATE.

ACRS stock Aclaris Therapeutics

ACRS stock
Aclaris Therapeutics

March 18, 2019
Change 20.43%
Chart period: 2018-12-19 - 2019-03-18





Will ACRS stock price go up or down on Wed, 20 Mar 2019?

Aclaris Therapeutics Forecast and Stock Analysis

Technical ACRS stock analysis for March 18, 2019.

Buy candidate since 2019-03-18
Shorts n/a
Cash n/a
Loans n/a
Beta 1.24
ROA -53.53

Aclaris Therapeutics gained 20.43% in the last trading day, rising from $5.63 to $6.78 The price has fallen in 6 of the last 10 days and is down by -0.44% for this period. Volume has increased in the last day along with the price, which is a positive technical sign, and, in total, 0.59 million more shares were traded than the day before. In total, 1.71 million shares bought and sold for approximately $11.60 million.

Close price at the end of the last trading day (Monday, 18th Mar 2019) of the ACRS stock was $6.78. This is 20.43% more than the trading day before Friday, 15th Mar 2019.

During day the stock fluctuated 33.87% from a day low at $5.61 to a day high of $7.51.

30 day high of the ACRS stock price was $7.51 and low was $5.49.
90 day high was $8.19 and low was $5.49.
52 week high for the Aclaris Therapeutics - $21.97 and low - $5.49.


Aclaris Therapeutics lies the upper part of a very wide and falling trend in the short term, and this will normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $7.04 will firstly indicate a slower falling rate, but may be the first sign of a trend shift. Given the current short-term trend, the stock is expected to fall -13.82% during the next 3 months and, with 90% probability hold a price between $4.61 and $6.07 at the end of this period.

Click here for today's Top 5 Trending Companies


Only positive signals in the chart today. Aclaris Therapeutics holds buy signals from both short- and long-term moving averages, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections down there will be some support from the lines at $5.91 and $6.59. A break down below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Friday March 15, 2019, which indicates further gains until a new top pivot has been found. Volume is rising along with the price. This is considered to be a good technical signal.

Access today's Top 5 Golden Star Companies

A buy signal from a double bottom formation was found on Friday March 15, 2019 with a target of $6.03. Despite the objective of the signal formation has been reached the stock may continue to perform well.

Relative Strength Index (RSI)

RSI14 is 54 and the stock is currently not being overbought or oversold

Access full RSI 14 and RSI 21 lists

Support & Resistance

Aclaris Therapeutics finds support from accumulated volume at $6.46.

Support: $6.46 Price: $6.78 Resistance: $6.86


This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $1.90 between high and low, or 33.87%. For the last week, the stock has had a daily average volatility of 11.79%.

Our recommended stoploss: $6.45 (-4.82%) (This stock has high daily movements and this gives high risk. There is a buy signal from pivot bottom found 1 days ago.)

Overall risk:

Very Low Low Medium High Very High

Evaluation: Buy Candidate

Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for this stock to perform well in the short-term. We have upgraded our recommendation for this stock since last evaluation from a Strong Sell Candidate to a Buy Candidate.

Weaker Buy Today ACRS ranks #2008 as BUY CANDIDATE. Stronger Buy
Today ACRS ranks #2008 as BUY CANDIDATE.